Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. develops medications targeting immune-mediated and metabolic diseases.

COM:ALDEYRA

Aldeyra Therapeutics, Inc.

Last Close

1.89

10/04 22:28

Market Cap

112.85M

Beta: -

Volume Today

2.96M

Avg: -